Background: Hydrops fetalis (HF) is a condition with a high mortality rate. The cause may be due to a variety of underlying diseases. In the majority of cases, death occurs antepartum and intrapartum. For those that are born alive, it is difficult to survive. The purpose of this study was to analyze the clinical manifestations, etiologies and outcomes of liveborn babies with hydrops fetalis.
Methods: From October 1995 through May 2001, 17 liveborn neonates that presented with HF were admitted to our neonate intensive care unit (NICU). We were retrospectively reviewed their records. Clinical data including gestational age (GA) at diagnosis and birth, birth weight, Apgar score, maternal and fetal presentations, laboratory data, etiology and outcome were retrospectively collected and analyzed.
Results: The mean GA at diagnosis was 30.5 weeks and the mean GA at birth was 33.8 weeks. The male to female ratio was 8:9. Most cases presented with ascites (12/17) and cardiomegaly (8/17). The most common problem faced by the liveborn HF neonates was cardiovascular anomalies (7/17). Seven of these liveborn HF neonates survived. The overall mortality rate of HF in this review was 59%. In comparison with survival cases, those that died were diagnosed earlier, had lower Apgar scores, had more severe acidosis, and had pericardial effusion.
Conclusion: Recent advances in prenatal ultrasonographic examinations have made early detection of fetal hydrops possible. The mortality rate of these liveborn hydropic neonates without receiving prenatal therapy was high. More effort in prenatal intervention is needed in order to decrease the mortality rate and improve the outcome of neonates with HF.
Download full-text PDF |
Source |
---|
Fertil Steril
December 2024
Department of Women's and Children's Health, Uppsala University, 751 85 Uppsala, Sweden; Reproduction Center, Uppsala University Hospital, 751 85 Uppsala, Sweden; Division of Obstetrics and Gynaecology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Objective: To explore whether progesterone supplementation during luteal phase and early pregnancy following a natural frozen-thawed embryo transfer cycle (NC-FET) affects perinatal outcomes.
Design: A secondary data analysis study based on two randomized control trials taking place during 2008-2011 and 2013-2018 at two university hospitals in Sweden.
Subjects: A total of 923 women undergoing a natural FET cycle.
Public Health Pract (Oxf)
December 2024
Rotunda Hospital, Dublin, Ireland.
Objective: To evaluate the differences in the antenatal and neonatal courses of maternal-infant dyads within a homeless population as compared to the general hospital population.
Design: This was a retrospective observational study.
Setting: A large single tertiary maternity hospital (8500 deliveries/year) in Ireland.
BMJ Open
December 2024
Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden
Objectives: The objectives of the study are to investigate infection risk in offspring born to women with systemic lupus erythematosus (SLE) compared with offspring born to women without SLE and examine the mediating role of preterm birth.
Design: This is a register-based cohort study.
Setting: Liveborn singletons born in Sweden, 2006-2021, were included in the study.
Hum Fertil (Camb)
December 2025
Center for Reproductive Medicine, Shandong University, Jinan, China.
To evaluate whether oocyte cryopreservation affects obstetric and perinatal outcomes, 350 donor oocyte recipients with live-born singletons were divided into three groups: frozen embryo transfer (FET) with fresh oocytes (n = 101), fresh embryo transfer (ET) with frozen oocytes (n = 190), FET with frozen oocytes (n = 59). Gestational age differed significantly (P = 0.025), with the FET with frozen oocytes group showing longer gestational age than FET with fresh oocytes group (276 days vs.
View Article and Find Full Text PDFJ Gynecol Obstet Hum Reprod
December 2024
URP FETUS 7328, Federation for Research into Innovative Explorations and Therapeutics in Utero, and LUMIERE Platform, University of Paris Cité, Paris, France; Department of Obstetrics and Gynecology, Pitié-Salpêtrière Hospital, APHP, Sorbonne University, Paris, France. Electronic address:
Background: Achondroplasia, due to a specific pathogenic variant in FGFR3, is the most common viable skeletal dysplasia and the diagnosis is mostly done in the prenatal period. Since 2021, the use of Vosoritide, a specific treatment for achondroplasia, validated in phase 3 placebo-controlled trials, has been recommended to significantly increase the height of children and infants. In the light of these new therapeutic prospects, a complete understanding of the pathophysiology of skeletal damages occurring from foetal life is required.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!